<?xml version="1.0"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/"><rdf:Description rdf:about="https://repozitorij.uni-lj.si/IzpisGradiva.php?id=181337"><dc:title>Estimates of current capacity for diagnosing and implementation of new treatment Alzheimer’s disease in Slovenia</dc:title><dc:creator>Županič,	Eva	(Avtor)
	</dc:creator><dc:creator>Stegnar,	Gašper	(Avtor)
	</dc:creator><dc:creator>Rakuša,	Martin	(Avtor)
	</dc:creator><dc:creator>Rus Prelog,	Polona	(Avtor)
	</dc:creator><dc:creator>Švab,	Igor	(Avtor)
	</dc:creator><dc:creator>Gregorič Kramberger,	Milica	(Avtor)
	</dc:creator><dc:subject>Alzheimer’s disease</dc:subject><dc:subject>dementia</dc:subject><dc:subject>disease-modifying treatment</dc:subject><dc:subject>healthcare organization</dc:subject><dc:subject>mild cognitive impairment</dc:subject><dc:description>Background: The limited efﬁcacy of current symptomatic treatments for Alzheimer’s disease (AD) leads many patientsto forgo medical help. However, new disease-modifying treatments (DMTs), such as donanemab and lecanemab, showpotential to change this.
Objective: To model the impact of these treatments on Slovenia’s healthcare system by analyzing patient ﬂow underboth current and enhanced capacities, assuming DMT availability.
Methods: The study estimates 76,923 potential DMT candidates aged 65 years and older with mild cognitive impairmentor mild AD. Using data from Slovenia’s three specialized centers for cognitive disorders, a Markov model simulated ﬁveﬁve-year scenarios: baseline, real-life, real-life with capacity enhancement, biomarker integration, and biomarker integra-tion with capacity enhancement.
Results: Waiting times for specialist evaluation would increase from the current 3–12 months to 1.8 years. The primarybottleneck is lumbar puncture with cerebrospinal ﬂuid (CSF) analysis, during which 64% of patients would become ineli-gible for DMT. The shortest waiting time to receive DMT occurs in the biomarker integration with capacity enhancementscenario, at 4 years, reducing ineligibility to 7%.
Conclusions: Current specialized outpatient facilities are limited, causing signiﬁcant bottlenecks, especially in CSF ana-lysis. Severe waiting times under current capacities mean many patients would progress to moderate or severe dementiaor die before receiving treatment. Plasma biomarkers offer a promising triage approach to guide patients toward lumbarpuncture or other conﬁrmatory diagnostics, potentially easing this critical bottleneck. Substantial infrastructure and work-force improvements are essential to ensure timely and equitable access to DMTs in Slovenia.</dc:description><dc:date>2026</dc:date><dc:date>2026-04-02 04:53:28</dc:date><dc:type>Članek v reviji</dc:type><dc:identifier>181337</dc:identifier><dc:language>sl</dc:language></rdf:Description></rdf:RDF>
